» Articles » PMID: 31205550

Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma

Overview
Journal J Cancer
Specialty Oncology
Date 2019 Jun 18
PMID 31205550
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

. Cyclin-dependent kinase inhibitor 3 (CDKN3) has been found playing a varying role in carcinogenesis, but its biological function in esophageal squamous cell carcinoma (ESCC) is unclear. The aim of this study was to demonstrate the role of CDKN3 in ESCC. Real-time PCR and Western blot was performed in 15 pairs of ESCC tissues and adjacent normal esophageal tissues. Then cell proliferation ability, cloning ability, cell cycle status and migration and invasion ability were explored in CDKN3 overexpressed TE1 cell line and CDKN3 siRNA transfected TE1 and KYSE70 cell lines. Finally, cell cycle related proteins CyclinD1, CDK4, pAKT, P53, P21, and P27 were tested by Western blot. mRNA level was higher in 11 ESCC tissues compared to adjacent normal tissues, and an increased protein expression was further detected in 8 of those 11 ESCC tissues. Functional assays showed that CDKN3 overexpression promoted ESCC cell proliferation, colony formation, migration and invasion, and facilitated G1/S transition. Opposite results were also got after transfected with CDKN3 siRNA. Cell cycle associated protein pAKT, CyclinD1, CDK4 and P27 were upregulated and P53, P21 and were downregulated under CDKN3 overexpression. All the protein levels were found changed in the opposite direction when CDKN3 expression was disturbed by siRNA. : Our study suggested that CDKN3 acted as an oncogene in human ESCC and may accelerate the G1/S transition by affecting CyclinD-CDK4 complex via regulating pAKT-p53-p21 axis and p27 independent of AKT.

Citing Articles

Characterization of breast cancer tumors in older patients who show de novo resistance to endocrine therapy.

Ishizuka Y, Horimoto Y, Yuan M, Ueki Y, Onagi H, Saeki H Sci Rep. 2024; 14(1):32116.

PMID: 39738567 PMC: 11686229. DOI: 10.1038/s41598-024-83895-2.


MiR-192-5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3.

Sahoo B, Mishra D, Tiwari S Noncoding RNA Res. 2024; 11:60-72.

PMID: 39736853 PMC: 11683246. DOI: 10.1016/j.ncrna.2024.11.003.


Evolution of the Cdk4/6-Cdkn2 system in invertebrates.

Yuki S, Sasaki S, Yamamoto Y, Murakami F, Sakata K, Araki I Genes Cells. 2024; 29(11):1037-1051.

PMID: 39380239 PMC: 11555623. DOI: 10.1111/gtc.13165.


Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities.

Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A World J Exp Med. 2024; 14(3):96269.

PMID: 39312702 PMC: 11372732. DOI: 10.5493/wjem.v14.i3.96269.


The role of Cyclin Dependent Kinase Inhibitor 3 () in promoting human tumors: Literature review and pan-cancer analysis.

Zhang C, Shen Q, Gao M, Li J, Pang B Heliyon. 2024; 10(4):e26061.

PMID: 38380029 PMC: 10877342. DOI: 10.1016/j.heliyon.2024.e26061.


References
1.
Yeh C, Lu S, Chen T, Peng C, Liaw Y . Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res. 2000; 60(17):4697-700. View

2.
Maak S, Jaesert S, Neumann K, von Lengerken G . Rapid communication: nucleotide sequence and physical mapping of the porcine cyclin-dependent kinase inhibitor 3 (CDKN3) gene. J Anim Sci. 2002; 80(6):1698-9. DOI: 10.2527/2002.8061698x. View

3.
Tran G, Sun X, Abnet C, Fan J, Dawsey S, Dong Z . Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2004; 113(3):456-63. DOI: 10.1002/ijc.20616. View

4.
Yu Y, Jiang X, Schoch B, Carroll R, Black P, Johnson M . Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 2007; 67(1):130-8. DOI: 10.1158/0008-5472.CAN-06-2478. View

5.
James M, Ray A, Leznova D, Blain S . Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol. 2007; 28(1):498-510. PMC: 2223302. DOI: 10.1128/MCB.02171-06. View